MedPath

Tivicay

These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY.TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspensionInitial U.S. Approval: 2013

Approved
Approval ID

44c4bbcc-fe93-4b4b-ad6a-12f46d2354ec

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 11, 2023

Manufacturers
FDA

RPK Pharmaceuticals, Inc.

DUNS: 147096275

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

dolutegravir sodium

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code53002-1810
Application NumberNDA204790
Product Classification
M
Marketing Category
C73594
G
Generic Name
dolutegravir sodium
Product Specifications
Route of AdministrationORAL
Effective DateOctober 7, 2022
FDA Product Classification

INGREDIENTS (11)

DOLUTEGRAVIR SODIUMActive
Quantity: 50 mg in 1 1
Code: 1Q1V9V5WYQ
Classification: ACTIM
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
POVIDONE, UNSPECIFIEDInactive
Code: FZ989GH94E
Classification: IACT
SODIUM STEARYL FUMARATEInactive
Code: 7CV7WJK4UI
Classification: IACT
FERRIC OXIDE YELLOWInactive
Code: EX438O2MRT
Classification: IACT
POLYVINYL ALCOHOL, UNSPECIFIEDInactive
Code: 532B59J990
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A CORNInactive
Code: AG9B65PV6B
Classification: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Tivicay - FDA Drug Approval Details